Cardiovascular diseases
Cardiovascular diseases and high cholesterol are constantly on the rise throughout the world.
Cardiometabolism & venous diseases
cardiometabolism
A strong commitment for 70 years
We help patients fight chronic diseases such as cardiovascular diseases, metabolic diseases, and venous diseases. We have built a strong reputation in these areas, and we continue to invest to benefit patients.
It is a commitment we have upheld for 70 years.
A major name in cardiometabolism
Cardiovascular diseases and related complications represent the leading cause of death throughout the world, responsible for claiming the lives of 17.7 million people, or 31% of all deaths. Faced with this public health challenge, we work day in, day out alongside patients and health care professionals.
We intend to maintain our leading position in this area by taking a strategic and innovative approach to managing the life cycle of our medicines. Our expertise in incremental innovation is leading to decisive progress, in particular with single pill combinations, which were designed to simplify treatment and improve adherence. We develop innovative digital services to improve patient care and help them keep up with their treatment.
5th
leading pharmaceutical group
in cardiology worldwide*
*IQVIA, Analytics Link / World 76 countries – MAT Q1-2024
1st
leading pharmaceutical group
in hypertension worldwide*
We have been also involved for many years in treating Type 2 diabetes, which accounts for around 90% of all diabetes cases in the world. As a complex illness that can evolve over time, it represents a major public health challenge. We are also behind several global initiatives to improve patient care and quality of life.
In February 2025, our cardiometabolism & venous diseases pipeline comprised 14 projects in clinical development
(Single Pill Combination & New Formulation)
Stepping up to the plate to improve adherence to treatments
In recent years, the health care sector has increasingly been focusing on ensuring patients stick to long-term treatments. Indeed, despite the existence of many therapeutic solutions, non-adherence is very frequent and greatly impacts patient health, which is why we take the situation very seriously.
We strongly believe that proper adherence is key to treating patients and improving care.
00:00 / 00:00
One of the keys to ensuring patients adhere to their treatment is increasing their engagement with the medicines they have been prescribed. That is why we initiated a project in collaboration with the doctors from the European Society of Hypertension (ESH), two patient organizations (Global Heart Hub and Senior International Health Association) and two institutions, including the European Commission, to develop a comprehensive digital solution to make it easier for patients to adhere to their treatment.
Did you know?
As a member of the Innovative Medicines Initiative (IMI) consortium, we actively contribute to the “BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe (BEAMER)” project. Kick-started in 2021, the project will run for five years. Its purpose is to identify patient behavioural types in order to provide solutions that will improve their adherence to treatments.
Got a question?
Want to report a side effect?
Check out our Pharmacovigilance page.